Adial Pharmaceuticals, Inc. (ADIL)
NASDAQ: ADIL · Real-Time Price · USD
6.00
0.00 (0.08%)
Sep 11, 2026, 4:00 PM EDT - Market closed
Adial Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 28.71 | 5.88 | 3.75 | 2.83 | 4 | 6.06 |
Cash & Short-Term Investments | 28.71 | 5.88 | 3.75 | 2.83 | 4 | 6.06 |
Cash Growth | 385.41% | 56.81% | 32.66% | -29.35% | -33.99% | 37.74% |
Prepaid Expenses | 0.13 | 0.3 | 0.31 | 0.37 | 0.35 | 0.39 |
Other Current Assets | - | - | - | - | 0.43 | 0.01 |
Total Current Assets | 28.85 | 6.18 | 4.06 | 3.2 | 4.78 | 6.46 |
Property, Plant & Equipment | - | - | - | - | - | 0.3 |
Long-Term Investments | 0.24 | 0.49 | 0.98 | 1.53 | - | - |
Goodwill | - | - | - | - | - | 0.25 |
Other Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0.46 |
Other Long-Term Assets | - | - | - | - | 0.95 | - |
Total Assets | 29.09 | 6.67 | 5.04 | 4.74 | 5.73 | 7.47 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 2.62 | 0.66 | 0.3 | 0.13 | 0.28 | 0.29 |
Accrued Expenses | 2.5 | 0.74 | 0.68 | 0.53 | 1.14 | 2.38 |
Current Portion of Leases | - | - | - | - | - | 0.05 |
Other Current Liabilities | - | - | - | - | 0.38 | 0.01 |
Total Current Liabilities | 5.12 | 1.4 | 0.98 | 0.65 | 1.79 | 2.72 |
Long-Term Leases | - | - | - | - | - | 0.21 |
Long-Term Deferred Tax Liabilities | - | - | - | - | - | 0.02 |
Other Long-Term Liabilities | 23.81 | - | - | - | 0.67 | 1.01 |
Total Liabilities | 28.93 | 1.4 | 0.98 | 0.65 | 2.46 | 3.97 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0 | 0 | 0 | 0 | 0 | 0.02 |
Additional Paid-In Capital | 105.6 | 95.25 | 86.06 | 72.88 | 66.95 | 54.43 |
Retained Earnings | -143.98 | -89.97 | -82 | -68.8 | -63.67 | -50.94 |
Shareholders' Equity | 0.16 | 5.28 | 4.07 | 4.08 | 3.28 | 3.51 |
Total Liabilities & Equity | 29.09 | 6.67 | 5.04 | 4.74 | 5.73 | 7.47 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | - | - | - | - | - | 0.26 |
Net Cash (Debt) | 28.71 | 5.88 | 3.75 | 2.83 | 4 | 5.81 |
Net Cash Growth | 385.41% | 56.81% | 32.66% | -29.35% | -31.07% | 31.90% |
Net Cash Per Share | 10.93 | 8.80 | 19.33 | 49.61 | 99.90 | 195.19 |
Filing Date Shares Outstanding | 2.63 | 1.43 | 0.26 | 0.16 | 0.05 | 0.04 |
Total Common Shares Outstanding | 2.63 | 1.11 | 0.26 | 0.07 | 0.04 | 0.03 |
Working Capital | 23.72 | 4.78 | 3.08 | 2.55 | 2.99 | 3.74 |
Book Value Per Share | -14.61 | 4.75 | 15.71 | 61.37 | 76.73 | 104.66 |
Tangible Book Value | -38.38 | 5.27 | 4.06 | 4.08 | 3.27 | 2.8 |
Tangible Book Value Per Share | -14.62 | 4.75 | 15.69 | 61.31 | 76.63 | 83.51 |